AT 017
Alternative Names: AT-017Latest Information Update: 03 Sep 2024
At a glance
- Originator Asieris Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Breast cancer; Cancer
Most Recent Events
- 03 Sep 2024 Preclinical trials in Breast cancer in China (unspecified route) prior to September 2024 (Asieris Pharmaceuticals Pipeline, September 2024)
- 03 Sep 2024 Preclinical trials in Cancer in China (unspecified route) prior to September 2024 (Asieris Pharmaceuticals Pipeline, September 2024)
- 29 Apr 2024 AT 017 is available for licensing as of 29 Apr 2024. https://asieris.com/partner/